Update shared on 17 Aug 2025
Fair value Increased 12%The notable upward revision in Agenus’s fair value target is primarily driven by significant improvements in net profit margin and a modest increase in forecasted revenue growth, resulting in a consensus analyst price target increase from $11.00 to $12.33.
What's in the News
- Agenus' botensilimab and balstilimab immunotherapy programs continue to show promising clinical progress, with new survival data and presentations at major oncology congresses, including a 42% two-year survival rate and 21-month median OS in immunotherapy-resistant MSS metastatic colorectal cancer.
- The FDA has agreed on a streamlined Phase 3 trial design (BATTMAN) for the BOT/BAL combination, waiving the requirement for a botensilimab monotherapy arm, though continued randomized controlled evidence is recommended for approval.
- Agenus entered a research collaboration with Noetik to develop predictive biomarkers for BOT/BAL efficacy, leveraging advanced AI-driven virtual cell models and multimodal tumor data.
- The company signed partnership and manufacturing agreements with Zydus Lifesciences, resulting in $75 million upfront for facility transfers, potential additional milestone payments, an exclusive manufacturing agreement, and a $16 million equity investment; Zydus gains exclusive rights to BOT/BAL in India and Sri Lanka.
- Agenus was removed from multiple Russell indexes, significantly reducing its index fund representation.
Valuation Changes
Summary of Valuation Changes for Agenus
- The Consensus Analyst Price Target has significantly risen from $11.00 to $12.33.
- The Net Profit Margin for Agenus has significantly risen from 13.98% to 16.25%.
- The Consensus Revenue Growth forecasts for Agenus has risen slightly from 7.7% per annum to 8.0% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.